kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human DNAM-1 /CD226 Protein, His Tag, 100µg  

Recombinant Human DNAM-1 /CD226 Protein, His Tag, 100µg

Recombinant Human DNAM-1 /CD226 Protein, Glu 19 - Asn 247, produced in human 293 cells (HEK293), His Tag

recombinant, human protein DNAM1,CD226

More details


Availability: within 7 days

300,00 €

DNAX accessory molecule 1 (DNAM-1), a single-pass type I membrane protein, is also known as CD226 antigen and platelet and T cell activation antigen 1 (PTA1), which contains 2 Ig-like C2-type (immunoglobulin-like) domains. DNAM-1 is a ~65 kDa glycoprotein expressed on the surface of natural killer cells, platelets, monocytes and a subset of T cells. DNAM-1 mediates cellular adhesion to other cells bearing its ligands, CD112 and CD155, and cross-linking DNAM-1 with antibodies causes cellular activation. Furthermore, DNAM-1 can interact with PVR and PVRL2.

Recombinant Human DNAM-1, His Tag (DN1-H52H6) is expressed from human 293 cells (HEK293). It contains AA Glu 19 - Asn 247 (Accession # NP_006557).
Predicted N-terminus: Glu 19

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 27.9 kDa. The protein migrates as 36-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Please refer to product data sheet.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment"
Taramasso, Bozzano, Casabianca et al
Front Immunol (2022) 13, 847816
(2) "Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas"
Sönmez, Wölfer, Holling et al
Sci Rep (2022) 12 (1), 6769
(3) "Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies"
Soldierer, Bister, Haist et al
Front Immunol (2022) 13, 847008
Showing 1-3 of 385 papers.